S-Calprotectin (S100A8S100A9)‎: A Potential Marker of Inflammation in Patients with Psoriatic Arthritis

الملخص EN

Objective.

To analyse levels of S100A8/S100A9 (calprotectin) and selected cytokines, in blood, in patients with psoriatic arthritis (PsA).

Methods.

Sixty-five patients with PsA were examined for clinical manifestations and laboratory measurements of S-calprotectin, ESR, hs-CRP, and selected cytokines.

Thirty-two patients had mono-/oligoarthritis and 33 had polyarthritis.

S-calprotectin, hs-CRP, and cytokines were measured using ELISA, immunoturbidimetry, and multiplex technology (Bio-Plex).

Patients with PsA were compared with 31 healthy controls.

Results.

S-calprotectin and hs-CRP levels were significantly higher in patients with PsA compared with controls ( P < 0.001 and P < 0.001 , resp.).

Patients suffering a polyarthritic disease pattern presented with significantly higher levels of S-calprotectin compared with controls and patients with mono-/oligoarthritis ( P < 0.001 and P = 0.017 , resp.).

The levels of S-calprotectin correlated with hs-CRP ( P < 0.001 ; r s = 0.441 ), swollen joint count ( P = 0.002 , r s = 0.397 ), and CXCL10 ( P = 0.046 , r s = 0.678 ) but not with any of the other cytokines evaluated.

In multiple logistic regression analysis, S-calprotectin was the only variable significantly associated with psoriatic arthritis ( P = 0.002 , OR = 1.006 , 95% CI = 1.002–1.010).

Conclusion.

S-calprotectin and hs-CRP levels were significantly higher in patients with PsA.

A polyarthritic disease pattern showed higher levels of S-calprotectin than mono-/oligoarthritis.

S-calprotectin is considered a potential marker of disease activity in patients with PsA.